Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms

Summary

This study aims to assess biomarkers and their related polymorphisms in the context of cancer-associated thromboembolism, with a particular focus on their interaction with the immune system. The roles of immune checkpoints, inflammatory and angiogenesis factors, as well as circulating immune cells will be elucidated. Additionally, our investigation extends to the exploration of long non-coding RNAs (LncRNAs) and genes associated with the coagulation vascular system. Initially, these aspects will be evaluated in the context of colorectal cancer, with the intention to expand our research to other solid tumors.

The identification of these biomarkers and genetic factors holds the potential to revolutionize therapeutic approaches for patients with cancer-associated thromboembolism, shedding light on their chemotherapy resistance. The effectiveness of combining immunotherapy with targeted inhibitors like Palbociclib and anticoagulants such as Rivaroxaban, among other potential interventions, will be assessed.

This study aims to make significant contributions to the understanding of these critical aspects, ultimately leading to the development of more effective treatment strategies for cancer patients.

Conditions

• Cancer
• Solid Tumor
• Thromboembolism
• Cardiovascular Diseases
• Immune System Diseases
• Inflammatory Diseases
• Colon Cancer
• Breast Cancer
• Prostate Cancer
• Hepatocellular Carcinoma
• Lung Cancer
• Chemotherapy
• Immunotherapy

Interventions

DRUG

Palbociclib

Palbociclib will be administered at a dose of 125 mg oral on a 21/7 cycle.

DRUG

Rivaroxaban

Rivaroxaban will be administered at a dosage of 15 mg intravenously twice a day for 21 days, followed by 20 mg once daily for the subsequent 21 days.

GENETIC

SNP

diagnostics of patients' carriers or not of the risk allele(s)

Sponsors & Collaborators

• Haykel Hospital

  collaborator UNKNOWN

• Lebanese University

  lead OTHER

Principal Investigators

• Nehman Makdissy, Professor · Lebanese University

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-02-01

Primary Completion

2024-12-31

Completion

2024-12-31

FDA Drug

Yes

Countries

• Lebanon

Study Locations